Education
About Us
Working with TipRanks
Follow Us
Mersana Therapeutics Inc (MRSN)
NASDAQ:MRSN
Earnings Data
Report Date
May 12, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-0.19Last Year’s EPS
-0.16Same Quarter Last Year
Strong Buy
Based on 6 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Mar 03, 2025
|% Change Since: -26.92%
|Next Earnings Date:May 12, 2025
Earnings Call Sentiment|Positive
The earnings call reflects a generally positive outlook for Mersana, highlighted by promising clinical data and a strong safety profile for Emi-Le, as well as increased collaboration revenues and reduced net loss. However, dose management challenges and market competition remain areas of concern.Company Guidance
During Mersana Therapeutics' Fourth Quarter and Year-End 2024 Conference Call, the company provided detailed guidance on its clinical progress and financial standing. Mersana's lead ADC, Emi-Le, showed promising initial clinical data with a confirmed objective response rate (ORR) of 23% in patients with high B7-H4 expression. The expansion portion of their Phase I trial has begun, focusing on triple-negative breast cancer (TNBC) patients who have previously undergone at least one topo-1 ADC treatment. The company is exploring doses up to 95 mg/m² and has amended trial protocols to address proteinuria. Financially, Mersana ended 2024 with $134.6 million in cash and equivalents, expecting their resources to support operations into 2026. The net cash used in operating activities decreased significantly, and collaboration revenue increased to $16.4 million in Q4 2024. The company plans to present additional clinical data later in the year and continues to advance its collaborations with J&J and Merck KGaA.Positive Initial Clinical Data for Emi-Le
Mersana reported positive initial clinical data for its lead Dolasynthen ADC, Emi-Le, and started the expansion portion of its Phase I trial. The company was also granted an additional Fast Track designation for a portion of the breast cancer population.
Strong Safety Profile of Emi-Le
Emi-Le demonstrated a differentiated safety profile with common treatment-related adverse events being manageable and without dose-limiting neutropenia, neuropathy, ocular toxicity, interstitial lung disease, or thrombocytopenia.
Confirmed Objective Responses
Confirmed objective responses were observed in all enrolled tumor types, including triple-negative breast cancer, with a 23% objective response rate in high B7-H4 expression patients.
Collaboration Revenue Increase
Collaboration revenue for the fourth quarter of 2024 was $16.4 million, up from $10.7 million in the same period in 2023, due to increased collaboration revenue under agreements with J&J, Merck KGaA, and GSK.
Reduced Net Loss
Mersana's net loss for the fourth quarter of 2024 was $14.1 million, compared to a net loss of $19.5 million for the same period in 2023, reflecting operational efficiencies.
---
MRSN Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
MRSN Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Mar 03, 2025 | $0.52 | $0.48 | -7.69% |
| Nov 13, 2024 | $2.20 | $2.63 | +19.55% |
| Aug 13, 2024 | $1.42 | $1.35 | -4.93% |
| May 09, 2024 | $3.40 | $2.46 | -27.65% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Mersana Therapeutics Inc (MRSN) report earnings?
Mersana Therapeutics Inc (MRSN) is schdueled to report earning on May 12, 2025, TBA Not Confirmed.
What is Mersana Therapeutics Inc (MRSN) earnings time?
Mersana Therapeutics Inc (MRSN) earnings time is at May 12, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is MRSN EPS forecast?
MRSN EPS forecast for the fiscal quarter 2025 (Q1) is -0.19.
---